Wuxi Biologics (Cayman)'s total assets for Q4 2024 were ¥56.98B, an increase of 1.55% from the previous quarter. WXIBF total liabilities were ¥11.50B for the fiscal quarter, a 0.30% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.